| Literature DB >> 26381658 |
Mirko Pham1, Dimitrios Oikonomou2, Benjamin Hornung1, Markus Weiler3,4, Sabine Heiland1,5, Philipp Bäumer1, Jennifer Kollmer1, Peter P Nawroth2,6, Martin Bendszus1.
Abstract
OBJECTIVE: The aim of this work was to localize and quantify alterations of nerve microstructure in diabetic polyneuropathy (DPN) by magnetic resonance (MR) neurography with large anatomical coverage.Entities:
Mesh:
Year: 2015 PMID: 26381658 PMCID: PMC5132066 DOI: 10.1002/ana.24524
Source DB: PubMed Journal: Ann Neurol ISSN: 0364-5134 Impact factor: 10.422
Figure 1Array of representative source images indicating segmented tibial fascicles within the sciatic nerve at the thigh level (upper row) and their continuation as the tibial nerve distally at the ankle level (lower row). Nerve lesions are conspicuous under hyperintense signal alteration, which was found to be an effect of increased proton spin density by quantitative signal analysis. Within symptomatic diabetic polyneuropathy (DPN) groups (mild/moderate or severe), there is a strong proximal focus of lesion predominance located at the thigh level (the white reference line in the bony anatomical scheme on the left indicates the slice position). A strong proximal‐to‐distal lesion gradient with a marked decrease at the distal ankle level (lower white reference line at the ankle level) and increasing fascicular involvement across groups of increasing DPN severity (from left to right) were observed. NDS = Neuropathy Disability Score; NSS = Neuropathy Symptom Score.
Figure 2Spatial mapping of lesion voxel count per position from the proximal thigh (slice position 1) to ankle levels (slice position 140). The spatial predominance of the lesion voxel burden in symptomatic diabetic polyneuropathy (DPN; mild/moderate or severe) is located proximally (thigh level slice positions 1–70) and is highest at this location for severe DPN. Increasing symptom severity is associated with an overall increase in the total lesion voxel burden, which is most pronounced proximally (at the thigh level, left side of the x‐axis) and less marked distally (at the ankle level, right side of the x‐axis). The differences in the proximal lesion count are significant for severe DPN (*p = 0.013) and mild‐to‐moderate DPN (**p = 0.003) compared to nondiabetic controls.
Demographic, Clinical, and Electrophysiological Data of Different Patient Groups
| Diabetes No DPN | DPN Mild or Moderate | DPN Severe | |
|---|---|---|---|
| N | 15 | 25 | 10 |
| Age | 59.1 ± 2.3 | 64.0 ± 1.5 | 66.9 ± 2.6a |
| Sex (M/F) | 9/6 | 16/9 | 7/3 |
| DM duration (yr) | 28.7 ± 3.6 | 23 ± 2.8 | 17.9 ± 3.6 |
| DM type I/II | 10/5 | 10/15 | 8/2 |
| NSS | 0.9 ± 0.2 | 3.8 ± 0.3b | 6.2 ± 0.6b |
| NDS | 0.1 ± 0.1 | 2.6 ± 0.5b | 7.4 ± 0.5b |
| Retinopathy | 26.7% | 32% | 40% |
| Nephropathy | 7% | 32% | 30% |
| CHD | 7% | 20% | 20% |
| Hypertension | 67% | 92% | 80% |
| Hyperlipidemia | 53% | 84% | 80% |
| Smoking | 27% | 8% | 20% |
| HbA1c (%) | 7.73 ± 0.29 | 7.45 ± 0.28 | 7.79 ± 0.55 |
| Cholesterol (mmol/L) | 177.4 ± 11.5 | 189.6 ± 12.2 | 177.9 ± 9.9 |
| Triglycerides (mmol/L) | 117.8 ± 20.7 | 236.5 ± 47.3 | 158.0 ± 38.9 |
| HDL (mmol/L) | 58.0 ± 4.5 | 60.5 ± 4.7 | 57.0 ± 8.4 |
| eGFR (ml/min/L) | 91.9 ± 3.8 | 82.3 ± 3.7 | 75.4 ± 4.2a |
| BMI (kg/m2) | 27.4 ± 1.0 | 28.7 ± 0.9 | 30.2 ± 1.2 |
| Sural NCV (m/s) | 43.6 ± 1.6 | 40.4 ± 2.2 | 35.5 ± 4.2a |
| Sural SNAP (μV) | 9.7 ± 1.9 | 3.6 ± 0.9b | 2.4 ± 1.2b |
| Tibial NCV (m/s) | 43.4 ± 1.3 | 44.0 ± 1.1 | 38.4 ± 2.7 |
| Tibial CMAP (mV) | 14.8 ± 1.8 | 9.3 ± 1.1a | 9.5 ± 2.5 |
| Peroneal NCV (m/s) | 43 ± 1.2 | 42.3 ± 1.0 | 39.2 ± 1.6 |
| Peroneal CMAP (mV) | 6.3 ± 0.8 | 4.1 ± 0.7a | 3.3 ± 0.9a |
All values are expressed as the mean ± standard error, median, or percentage. Values of the symptomatic groups (middle and right columns) were tested pairwise against the corresponding values in the patient group without symptoms (Diabetes ‐ no DPN, left).
Statistical significance at a p < 0.05 and b p < 0.01.
DM = diabetes mellitus; NSS = Neuropathy Symptom Score; NDS = Neuropathy Disability Score; CHD = coronary heart disease; HbA1c = glycosylated hemoglobin; HDL = high‐density lipoprotein; eGFR = estimated glomerular filtration rate; BMI = body mass index; NCV = nerve conduction velocity; SNAP = sensory nerve action potential; CMAP = compound motor action potential; DPN = diabetic polyneuropathy.
Mean Lesion Voxel Counts Per Slice at Proximal and Distal Locations for Each Group
| Control (nondiabetic) | Diabetic Control (no DPN) | Mild/Moderate DPN | Severe DPN | |
|---|---|---|---|---|
| Proximal lesion count | 18 ± 3.6 | 21 ± 5.5 | 35 ± 4.0 | 57 ± 18.4 |
| Test statistics (vs controls) |
|
|
| |
| Distal lesion count | 8 ± 1.4 | 8 ± 2.9 | 12 ± 1.8 | 22 ± 8.1 |
| Test statistics (vs controls) |
|
|
|
Post‐hoc pair‐wise comparisons were performed for each group and location against the age‐/sex‐matched nondiabetic control group.
DPN = diabetic polyneuropathy.
Figure 3Ordered logistic regression analysis was significant for the quantitative microstructural marker of proton spin density (ρ/rho). This plot illustrates the cumulative probabilities predicted from the logistic regression model for different clinical stages of diabetic polyneuropathy (DPN) as functions of quantitated proton spin density (x‐axis). An increase of 102 proton spins was significantly associated (p < 0.001) with an odds ratio of 2.9 (95% confidence interval: 2.4–3.5) for predicting higher symptom severity.